The Clinical Application of Neoantigens in Esophageal Cancer

Frontiers in Oncology

Yong Yuan¹  Yi-Min Gu¹  Long-Qi Chen¹  Yue Zhuo² 

[1] Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, China;West China School of Medicine, Sichuan University, Chengdu, China;

关键词: esophageal cancer;    immunotherapy;    neoantigen;    cancer vaccine;    adoptive cell therapy;   

DOI  :  10.3389/fonc.2021.703517

来源: DOAJ

【 摘 要 】

Esophageal cancer (EC) is a common malignant tumor with poor prognosis, and current treatments for patients with advanced EC remain unsatisfactory. Recently, immunotherapy has been recognized as a new and promising approach for various tumors. EC cells present a high tumor mutation burden and harbor abundant tumor antigens, including tumor-associated antigens and tumor-specific antigens. The latter, also referred to as neoantigens, are immunogenic mutated peptides presented by major histocompatibility complex class I molecules. While current genomics and bioinformatics technologies have greatly facilitated the identification of tumor neoantigens, identifying individual neoantigens systematically for successful therapies remains a challenging problem. Owing to the initiation of strong, specific tumor-killing cytotoxic T cell responses, neoantigens are emerging as promising targets to develop personalized treatment and have triggered the development of cancer vaccines, adoptive T cell therapies, and combination therapies. This review aims to give a current understanding of the clinical application of neoantigens in EC and provide direction for future investigation.

【 授权许可】

Unknown